NCT05314231View on ClinicalTrials.gov

Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

June 29, 2022

Primary Completion Date

May 31, 2023

Study Completion Date

May 31, 2023

Conditions
Proteinuria
Interventions
DRUG

ALXN1720

All enrolled participants will receive a single dose of ALXN1720 on Day 1 followed by a Post-treatment and Follow-up Period (92 days).

Trial Locations (2)

14068

Clinical Trial Site 2, Anyang-si

03080

Clinical Trial Site 1, Seoul

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY